Hepatitis B immunoglobulin
Phase 2Small molecule
GileadHepatitis B immunoglobulin is one of 83 small molecule programs targeting Prevention. It is currently in Phase 2.
2
Indications
4
Total Trials
1
Active Trials
82
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
81 competitors in Chronic Hepatitis
#DrugCompanyPhaseTrials
1PEG-Intron
Merck & Co.Phase 3
PEG-IFNα
GileadPhase 3
Bepirovirsen
GSKPhase 3
Opdivo
Bristol-Myers SquibbPhase 2
Hydronidone
BBeijing Continent Pharmaceutical Co, Ltd.
Phase 3
Pegylated Interferon Alfa
Merck & Co.Phase 3
NA Therapy
GSKPhase 3
AHB-137
AAusper Biopharma Co., Ltd.
Phase 3
Azvudine
HHenan Genuine Biotech Co., Ltd.
Phase 3
Brelovitug
MMirum Pharmaceuticals, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Hepatitis2 trials
Hepatitis B1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Hepatitis B immunoglobulin. EMBL-EBI & Wellcome Sanger Institute.
- [4]